IMPACT Therapeutics, Inc (07630.HK): Expected H1 Revenue Growth of 276%–359% and Loss Narrowing by 22%–37%

NewTimeSpace News: On 11 August 2026, IMPACT Therapeutics, Inc (07630.HK) released a profit forecast. Based on preliminary assessment of the unaudited consolidated management accounts, the Group expects first-half revenue of approximately RMB94.7 million to RMB116 million, rising by about 276% to 359% compared with the same period last year. Losses for the period are projected at roughly RMB81.7 million to RMB99.9 million, narrowing by around 22% to 37% year-on-year.

According to the announcement, the changes are mainly attributable to the inclusion of selinapali in the National Medical Insurance Catalogue at the start of 2026, with accelerated commercialisation driving substantial sales growth. A milestone payment under the collaboration agreement with Eikon Therapeutics for IMP1734 was recognised as licensing revenue following entry into Phase II clinical trials. In addition, interest expenses on ordinary share redemption liabilities decreased, representing a one-off factor.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.